New Questions Raised Over Sterilization Device
The implant, made by Bayer, is being questioned after a study finds women with it were 10 times as likely to need new operations. Elsewhere, an Alzheimer's study is held up by a legal dispute.
The Wall Street Journal:
Study Raises New Concerns About Bayer Sterility Device
In the first large, controlled study of Bayer AG’s sterility device Essure, researchers found that women who have had it implanted were 10 times as likely to need new operations as women who got standard sterility surgery. Women have spoken of debilitating pain and allergic reactions to the Essure implants, including at a Food and Drug Administration workshop last month. Some 750,000 or more women world-wide have gotten the Essure implants, but it has been difficult to assess the scope of the problem until this study. (Burton, 10/13)
The Wall Street Journal:
Alzheimer’s Research Effort Is Ensnared In Legal Dispute
Caught in the crossfire of the legal dispute is the Alzheimer’s Disease Collaborative Study, a $100 million-plus research effort to test new drugs, formed between the University of California, San Diego and the National Institute on Aging, a federal agency, and partly funded by corporate grants from companies like Eli Lilly & Co. Neither the companies nor the NIH are named as defendants. (Wang and Loftus, 10/14)
